Supernus Pharma (SUPN) Misses Q4 EPS by 54c ; Offers Guidance

Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of $0.02, $0.54 worse than the analyst estimate of $0.56. Revenue for the quarter came in at $156 million versus the consensus estimate of $155.83 million.

GUIDANCE:

Supernus Pharma sees FY2024 revenue of $580-620 million, versus the consensus of $622.5 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Accenture downgraded by TD Cowen on AI concerns
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge